Updated:
MDxHealth
MDxHealth is a precision diagnostics company providing molecular tests for urologic cancers, including Confirm mdx and GPS, with over 500,000 patients...
MDxHealth
MDxHealth was founded as a spin-off from Ghent University in Belgium, with operations now spanning the U.S. and Europe. The firm markets a suite of molecular diagnostic tests for urologic diseases, including prostate cancer and urinary tract infections, and reports having impacted over 500,000 patients (per the firm). The firm's product line includes Confirm mdx, which addresses false-negative biopsies by analyzing tissue from an initial negative core; GPS (Genomic Prostate Score), a tissue-based test that predicts adverse pathology and 20-year outcomes; and Resolve mdx, a urine-based test for UTI treatment selection. These are covered by Medicare and commercial insurers in the U.S., and the firm publishes peer-reviewed level 1 evidence in journals such as European Urology and Journal of Urology (Altss research). Its laboratory operations span Irvine, California, Plano, Texas, and Nijmegen, Netherlands. MDxHealth employs over 200 staff and is led by CEO Michael McGarrity (per SEC filings). The firm is publicly traded on Euronext Brussels and the Nasdaq (ticker MDXH). Its board includes representatives from Ahok BV and Hilde Windels BVBA, reflecting Belgian institutional holdings. In 2024, the firm launched an at-home collection kit for its Exo mdx urine test (Altss research). MDxHealth occupies a niche in urologic oncology diagnostics, competing with Exact Sciences' Oncotype DX and other labs. Its structural differentiator is a dual-hemisphere lab network enabling both European and U.S. commercial operations, coupled with a proprietary methylation-based platform that differentiates it from standard PCR-based tests.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Irvine
Corporate office
Irvine, CA, United States
Additional offices
Herstal, Belgium · Nijmegen, Netherlands · Plano, TX, United States · Waltham, MA, United States
Principals
Wim Van Criekinge
Chief Scientific Officer
Adam J. Cole
Physician (featured speaker)
Eric A. Klein
Physician (featured speaker)
Sector focus
Frequently asked questions
Who runs investment decisions at MDxHealth?
MDxHealth is a publicly traded company (Nasdaq: MDXH) led by CEO Michael McGarrity. Investment decisions are made by the board of directors and management team, not by a single family office. The firm's board includes representatives from Ahok BV and Hilde Windels BVBA, which are institutional investors rather than controlling families.
How does MDxHealth source proprietary deal flow?
MDxHealth does not operate as an investment firm. Its growth is driven by organic R&D and partnerships with academic institutions, such as Ghent University, and collaborations with clinical networks. The firm does not make external investments.
Is MDxHealth structured as a single family office or does it operate more like a venture firm?
Neither. MDxHealth is a publicly traded medical diagnostics company listed on Nasdaq and Euronext Brussels. It is not a family office or venture firm; it develops and commercializes molecular diagnostic tests for urologic cancers.
Does MDxHealth participate in fund commitments or only direct deals?
MDxHealth does not make fund commitments or direct investments. It raises capital through public equity markets and debt financing to fund its commercial operations and clinical trials.
Which sectors does MDxHealth explicitly avoid?
MDxHealth focuses solely on urologic oncology diagnostics. It does not operate in other therapeutic areas, such as cardiology or infectious disease, aside from its UTI test Resolve mdx.
How is MDxHealth related to Ghent University?
MDxHealth was originally spun off from Ghent University in Belgium. Professor Wim Van Criekinge, who served as Chief Scientific Officer, is a professor at Ghent University and holds several patents related to the firm's methylation technology.
Where does the underlying wealth come from?
MDxHealth is not a family office and has no disclosed wealth origin. The company is publicly traded and owned by institutional and retail shareholders.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: